MYRIAD GENETICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
MYRIAD GENETICS, INC. (MYGN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-31
- MYRIAD GENETICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $1.10M, a 60.71% decline year-over-year.
- MYRIAD GENETICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.00M, a 64.29% decline year-over-year.
- MYRIAD GENETICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.10M, a 60.71% decline year-over-year.
- MYRIAD GENETICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.00M, a 56.52% decline year-over-year.
- MYRIAD GENETICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $7.70M, a 18.95% decline from fiscal 2024.
- MYRIAD GENETICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $9.50M, a 15.93% decline from fiscal 2023.
- MYRIAD GENETICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $11.30M, a 3.42% decline from fiscal 2022.
- MYRIAD GENETICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $11.70M, a 8.59% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $2.10M 10-Q · filed 2026-07-31 | $3.20M derived: sum of 3 quarters · filed 2026-07-31 | $4.20M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $1.00M 10-Q · filed 2026-05-06 | $2.10M derived: sum of 2 quarters · filed 2026-05-06 | $3.10M derived: sum of 3 quarters · filed 2026-05-06 | $5.90M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.10M derived: sum of 2 quarters · filed 2026-02-24 | $4.90M derived: sum of 3 quarters · filed 2026-07-31 | $7.70M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.80M derived: sum of 2 quarters · filed 2026-07-31 | $6.60M 10-Q · filed 2025-11-04 | $9.40M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $5.60M 10-Q · filed 2026-07-31 | $8.40M derived: sum of 3 quarters · filed 2026-07-31 | $10.70M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $2.80M 10-Q · filed 2026-05-06 | $5.60M derived: sum of 2 quarters · filed 2026-05-06 | $7.90M derived: sum of 3 quarters · filed 2026-05-06 | $10.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.10M derived: sum of 2 quarters · filed 2026-02-24 | $7.20M derived: sum of 3 quarters · filed 2026-02-24 | $9.50M 10-K · filed 2026-02-24 |
| 2024-09-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.40M derived: sum of 2 quarters · filed 2025-11-04 | $6.70M 10-Q · filed 2025-11-04 | $9.40M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $4.40M 10-Q · filed 2025-08-06 | $7.10M derived: sum of 3 quarters · filed 2026-02-24 | $9.90M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $2.30M 10-Q · filed 2025-05-07 | $5.00M derived: sum of 2 quarters · filed 2026-02-24 | $7.80M derived: sum of 3 quarters · filed 2026-02-24 | $10.70M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.50M derived: sum of 2 quarters · filed 2026-02-24 | $8.40M derived: sum of 3 quarters · filed 2026-02-24 | $11.30M 10-K · filed 2026-02-24 |
| 2023-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $5.70M derived: sum of 2 quarters · filed 2024-11-08 | $8.60M 10-Q · filed 2024-11-08 | $11.70M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $5.80M 10-Q · filed 2024-08-07 | $8.90M derived: sum of 3 quarters · filed 2025-02-28 | $11.80M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $2.90M 10-Q · filed 2024-05-08 | $6.00M derived: sum of 2 quarters · filed 2025-02-28 | $8.90M derived: sum of 3 quarters · filed 2025-02-28 | $11.50M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $6.00M derived: sum of 2 quarters · filed 2025-02-28 | $8.60M derived: sum of 3 quarters · filed 2025-02-28 | $11.70M 10-K · filed 2025-02-28 |
| 2022-09-30 | $2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $5.50M derived: sum of 2 quarters · filed 2023-11-07 | $8.60M 10-Q · filed 2023-11-07 | $11.60M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $5.70M 10-Q · filed 2023-08-04 | $8.70M derived: sum of 3 quarters · filed 2024-02-28 | $11.70M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $3.10M 10-Q · filed 2023-05-04 | $6.10M derived: sum of 2 quarters · filed 2024-02-28 | $9.10M derived: sum of 3 quarters · filed 2024-02-28 | $12.40M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $6.00M derived: sum of 2 quarters · filed 2024-02-28 | $9.30M derived: sum of 3 quarters · filed 2024-02-28 | $12.80M 10-K · filed 2024-02-28 |
| 2021-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $6.30M derived: sum of 2 quarters · filed 2022-11-02 | $9.80M 10-Q · filed 2022-11-02 | $12.90M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $6.80M 10-Q · filed 2022-08-05 | $9.90M derived: sum of 3 quarters · filed 2023-03-01 | $13.20M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $3.50M 10-Q · filed 2022-05-06 | $6.60M derived: sum of 2 quarters · filed 2023-03-01 | $9.90M derived: sum of 3 quarters · filed 2023-03-01 | $13.20M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $3.10M derived: 10-K 6 month − 10-Q 3 month · filed 2023-03-01 | $6.40M 10-K · filed 2023-03-01 | $9.70M derived: sum of 3 quarters · filed 2023-03-01 | $12.70M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-09-30 | $3.30M 10-Q · filed 2020-11-09 | $6.60M derived: sum of 2 quarters · filed 2021-08-04 | $9.60M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $6.30M 10-Q · filed 2021-08-04 | $0.00 10-K · filed 2023-03-01 | |
| 2020-03-31 | $3.00M 10-Q · filed 2021-05-05 | |||
| 2019-09-30 | $3.20M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $0.00 10-K · filed 2022-02-25 | |||
| 2018-06-30 | $0.00 10-KT · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |